Life-threatening ventricular arrhythmia prediction in patients with dilated cardiomyopathy using explainable electrocardiogram-based deep neural networks

Arjan Sammani †1, Rutger R. van de Leur †1, Michiel T.H.M. Henkens ‡2,3, Mathias Meine1, Peter Loh1, Rutger J. Hassink1, Daniel L. Oberski1,4, Stephane R.B. Heymans2,3,5, Pieter A. Doevendans1,3,6, Folkert W. Asselbergs1,7, Anneline S.J.M. te Riele †1, and René van Es †1*†

1Department of Cardiology, University Medical Centre Utrecht, University of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; 2Department of Cardiology, CARIM, Maastricht University Medical Centre, Maastricht, The Netherlands; 3Netherlands Heart Institute (NLHI), Utrecht, The Netherlands; 4Department of Methodology and Statistics, Faculty of Social Sciences, Utrecht University and University Medical Centre Utrecht, Utrecht, The Netherlands; 5Department of Cardiovascular Research, University of Leuven, Leuven, Belgium; 6Central Military Hospital, Utrecht, The Netherlands; and 7Institute of Cardiovascular Science and Institute of Health Informatics, Faculty of Population Health Sciences, University College London, London, UK

Received 3 December 2021; accepted after revision 10 April 2022; online publish-ahead-of-print 28 June 2022

Aims

While electrocardiogram (ECG) characteristics have been associated with life-threatening ventricular arrhythmias (LTVA) in dilated cardiomyopathy (DCM), they typically rely on human-derived parameters. Deep neural networks (DNNs) can discover complex ECG patterns, but the interpretation is hampered by their ‘black-box’ characteristics. We aimed to detect DCM patients at risk of LTVA using an inherently explainable DNN.

Methods and results

In this two-phase study, we first developed a variational autoencoder DNN on more than 1 million 12-lead median beat ECGs, compressing the ECG into 21 different factors (F): FactorECG. Next, we used two cohorts with a combined total of 695 DCM patients and entered these factors in a Cox regression for the composite LTVA outcome, which was defined as sudden cardiac arrest, spontaneous sustained ventricular tachycardia, or implantable cardioverter-defibrillator treated ventricular arrhythmia. Most patients were male (n = 442, 64%) with a median age of 54 years [interquartile range (IQR) 44–62], and median left ventricular ejection fraction of 30% (IQR 23–39). A total of 115 patients (16.5%) reached the study outcome. Factors F8 (prolonged PR-interval and P-wave duration, \( P = 0.005 \)), F15 (reduced P-wave height, \( P = 0.04 \)), F25 (increased right bundle branch delay, \( P = 0.02 \)), F30 (P-wave axis \( P < 0.005 \)), and F32 (reduced QRS-T voltages \( P = 0.03 \)) were significantly associated with LTVA.

Conclusion

Inherently explainable DNNs can detect patients at risk of LTVA which is mainly driven by P-wave abnormalities.

Keywords

Dilated cardiomyopathy • Deep neural network • Prognosis • Sudden cardiac death • Implantable cardioverter-defibrillator

* Corresponding author: E-mail address: r.vanes-2@umcutrecht.nl
† Contributed equally as first authors.

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
What’s new?

- This is the first study to use an inherently interpretable deep neural network (variational autoencoder, VAE) for the prediction of life-threatening arrhythmias in patients with dilated cardiomyopathy using raw electrocardiogram (ECG) signals.
- The FactorECG summarizes the median beat ECG, including most of its features, into 21 generative factors of variation. This novel strategy allows to simultaneously evaluate most characteristics that make up an ECG automatically, rather than using selected and human-derived ECG features.
- While the VAE encompasses complete electrocardiograms, visualization of pivotal ECG features showed that network predictions were mainly driven by P-wave abnormalities.
- These P-wave abnormalities did not correlate with their anatomical analogues, such as left atrial dimensions, suggesting an electrophysiological substrate.

Introduction

Patients with non-ischaemic dilated cardiomyopathy (DCM) have an estimated annual risk of life-threatening ventricular arrhythmias (LVTAs) of 4.5% and may potentially benefit from implantable cardioverter-defibrillator (ICD) implantation. A novel risk model (DCM-SVA risk) for predicting LTVAs was recently published and includes easily accessible clinical parameters, such as the history of non-sustained ventricular tachycardia (VT), QRS duration, and left ventricular ejection fraction (LVEF). More complex electrocardiogram (ECG) characteristics such as fragmented QRS waves, heart rate variability, and T-wave alternans have also been associated with LTVA, but rely on manually derived ECG parameters that remain difficult to standardize, hampering their integration into daily clinical practice. By using raw ECG signals and machine learning techniques, manual feature extraction is not necessary. Moreover, novel and more subtle parameters may be detected.

Deep neural networks (DNN) have proven to be potent machine learning algorithms for diagnostic classification tasks using raw ECG signals. Previous studies using DNNs on raw ECG signals in cardiomyopathies report high performance in disease classification and triaging. However, because of the inherent lack of ‘explainability’ of DNNs, clinical implementation remains limited. Different techniques may assist in interpreting DNNs. A recently introduced pipeline for fully explainable DNNs for ECG analysis uses variational autoencoders (VAEs), that can compress the ECG into a lower number of explanatory and independent generative factors (FactorECG), which can subsequently be used in interpretable algorithms (such as Cox regression).

In this study, we aimed (i) use an inherently interpretable DNN for predicting potentially LTVA based on ECGs in patients with non-ischemic DCM, assess its added value above conventional ECG parameters and current guidelines and (ii) interpret the model by visualizing pivotal ECG features.

Methods

Study participants

In this retrospective cohort study, we included consecutive adult patients with DCM as defined by the European Society of Cardiology (ESC) guidelines were included from the UMCU and MUMC+.

Only patients with a baseline non-paced 12-lead ECG acquired before left ventricular assist device (LVAD) implantation or heart transplantation (HTx) were eligible. Patients with a cardiac resynchronization therapy (CRT) were excluded, as it positively affects reverse remodelling which may reduce arrhythmias. This study was conducted in accordance with the principles laid out in the Declaration of Helsinki and in line with guidelines provided by ethics committees and the national GDPR legislature. The participants from the UMCU cohort were included using the opt-out procedure. The UMCU cohort was exempt from the Medical Research Involving Human Subjects Act (WMO) as per the judgement of the Medical Ethics Committee (18/446 and 19/222 UMCU, The Netherlands) including the requirement for informed consent. The participants of the Maastricht cohort signed informed consent at enrolment.

Data acquisition

For all subjects, the ECG closest to the date of the first presentation was obtained which was considered ‘baseline’ for the purpose of this study. The median time between diagnosis and ECG was 0 (IQR 0–28) days. All ECGs were exported from the MUSE ECG system (version 8; GE Healthcare, Chicago, IL, USA) in raw voltage format. The recordings were made using a General Electric MAC V, 5000 or 5500 device and acquired at either 250 or 500 Hz. Resampling to 500 Hz was performed via linear interpolation and transformation into 1.2-s median beats was achieved by aligning all QRS-complexes of the same shape (e.g. excluding premature ventricular complexes) and taking the median voltage to generate a representative P-QRS-T complex. Echocardiographic measurements were extracted from the electronic health record using methods described before.11

Pre-training and explainability of the variational autoencoder

A two-phase approach was used in this study, where a VAE was first pre-trained on the complete UMCU ECG dataset, and then used in the training step to find associations with LTVA (Figure 1). VAES are unsupervised deep learning encoder–decoder convolutional neural networks that are optimized to reconstruct their training data with a lower-dimensional representation (i.e. using less data) than the original training data (in this case ECGs). The current VAE network is enforced with a specific function to reach maximum disentanglement of lower-dimensional representation (i.e. to produce generative factors in the ECG that operate independently: the FactorECG).12 Resting 12-lead 10-s ECGs of 251 473 unique patients (1 114 331 ECGs) were exported from the UMCU ECG system and used for pre-training of the VAE. In a prior study, the optimal number of dimensions was found to be 21, considering the trade-off of good reconstruction disentanglement and encoding for visible ECG abnormalities.8

Explainability of the individual factors was obtained on a model level using factor traversals. Starting with a mean FactorECG for this population (i.e. the mean value of the 21 ECG factors), a median beat ECG is reconstructed using the decoder. Subsequently, for each individual ECG factor, values between −4 and 4 are added and ECGs are reconstructed for every value. Meanwhile, values for the other factors are kept constant. This way we are able to visualize the effect of a single ECG factor on the median beat ECG morphology in this cohort (Figure 2). On the individual patient level, explainability is obtained by
investigating the FactorECG values of that specific ECG. A tool to visualize the factors interactively can be found at https://dcm.ecgx.ai. The architecture and model training process were implemented using PyTorch (version 1.7.0 + cu110) in Python (version 3.6.7).

**Outcome definitions**

The primary study outcome was LTVA, defined as the composite outcome of sustained ventricular tachycardia (VT) >100 b.p.m. lasting >30 s or with hemodynamic compromise, ventricular fibrillation (VF), sudden cardiac death (SCD, defined as the death of cardiac origin that occurred unexpectedly within 1 h after the onset of new symptoms) or appropriate ICD therapy (defined as any ICD therapy delivered by the device in response to VT or VF according to stored intracardiac electrograms).3

**Statistical analyses**

For the baseline table, mean ± SD or median (interquartile range) were used where appropriate. Missingness in baseline data was not addressed. Each baseline ECG’s generative factors (the FactorECGs, as computed by the VAE encoder) were included in a Cox proportional hazards model (Figure 1). All patients had a digitalized ECG available. The proportional hazards assumption was tested. Hazard ratios (HR) were reported, and 95% confidence intervals (CIs) were computed using 2000 bootstrap samples. To rule out that the VAE model was solely considering already established ECG characteristics (ventricular rate, PR-interval, QRS-duration, and Bazett corrected QT-interval), a Cox proportional hazard model was also fitted using these variables in a complete case analysis. The correlations of the significant ECG factors were plotted against the left atrial (LA) dimension and left atrial volume index (LAVI) measured on standard care clinical echocardiography using both the first (closest to baseline) and last (closest to follow-up) available measurements.11 Additionally a Kaplan–Meier curve was plotted for one of the significant VAE generative factors. All analyses were performed using Python (version 3.8.5).

**Results**

**Patient characteristics**

Baseline characteristics stratified by centre and outcome are depicted in Table 1. A total of 695 patients were included from the UMUC and MUMC+, which were predominantly male (n = 442, 64%) with a median age of 54 years [interquartile range (IQR) 44–62] and median LVEF of 30% (IQR 23–39%). A total of 115 (17%) reached the study outcome in both centres combined during
Table 1 Patient characteristics at baseline (first evaluation) stratified by centre and outcome

|                          | UMCU all (n = 317) | UMCU without LTVA (n = 227) | UMCU with LTVA (n = 90) | MUMC all (n = 378) | MUMC without LTVA (n = 353) | MUMC with LTVA (n = 25) |
|--------------------------|--------------------|-----------------------------|-------------------------|-------------------|-----------------------------|-------------------------|
| Age (years), median (Q1–Q3) | 52 (42–61)         | 51 (41–60)                  | 52 (42–62)              | 55 (47–63)        | 56 (47–63)                  | 54 (49–63)              |
| Male sex                 | 195 (62%)          | 129 (57%)                   | 66 (74%)                | 247 (65%)         | 228 (65%)                   | 19 (76%)                |
| NYHA-class               |                    |                             |                         |                   |                             |                         |
| I                        | 53 (20%)*          | 36 (18%)*                   | 17 (23%)*               | 158 (42%)         | 150 (43%)                   | 8 (32%)                 |
| II                       | 102 (39%)*         | 71 (36%)*                   | 31 (41%)*               | 175 (46%)         | 163 (47%)                   | 12 (48%)                |
| III                      | 79 (30%)*          | 56 (28%)*                   | 23 (32%)*               | 37 (10%)          | 32 (9%)                     | 5 (20%)                 |
| IV                       | 27 (10%)*          | 36 (18%)*                   | 4 (5%)*                 | 8 (2%)            | 8 (2%)                      | 0 (0%)                  |
| Diabetes mellitus        | 42 (13%)           | 31 (13%)                    | 11 (12%)                | 52 (14%)          | 50 (14%)                    | 2 (8%)                  |
| Hypercholesterolemia     | 37 (13%)           | 26 (13%)                    | 11 (13%)                | 41 (11%)          | 38 (11%)                    | 3 (12%)                 |
| (Ever) smoked            | 203 (64%)          | 145 (64%)                   | 57 (63%)                | 77 (20%)          | 72 (20%)                    | 5 (20%)                 |
| History of LTVA          | 42 (13%)           | 17 (7%)                     | 25 (27%)                | 8 (2%)            | 7 (2%)                      | 1 (4%)                  |
| Family history of DCM    | 133 (42%)          | 97 (43%)                    | 36 (40%)                | 47 (14%)          | 39 (11%)                    | 8 (32%)                 |
| ICD implantation         | 233 (74%)          | 145 (63%)                   | 88 (97%)                | 0 (0%)            | 0 (0%)                      | 0 (0%)                  |
| LVEF (%), median (Q1–Q3) | 25 (20–33)         | 25 (20–33)                  | 25 (19–32)              | 33 (25–40)        | 28 (22–37)                  | 33 (25–41)              |
| MRI LGE                  | 84 (56%**)         | 60 (51%*)                   | 24 (71%**)              | n/a               | n/a                         | n/a                     |

Baseline characteristics of the included cohorts. NYHA, New York Heart Association; LTVA, life-threatening ventricular arrhythmia; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; *, of valid, in patients for which a NYHA class was noted in the electronic health record; MRI LGE, magnetic resonance imaging late gadolinium enhancement; **, of valid, in patients with cardiac MRIs.

Prediction of LTVA with established ECG variables

Established ECG variables (such as ventricular rate, PR-interval, QRS-duration, and QTc-time) were entered in a ‘baseline’ Cox regression model controlled for guideline indication [complete case analysis with n = 577, excluding patients without a measurable PR-interval (n = 118, due to atrial fibrillation/flutter)]. This baseline model had a C-statistic of 0.58 (95% CI 0.52–0.64) and no significant effects of ventricular rate [HR 0.94 per 10 beat/s increase (95% CI 0.81–1.09), P = 0.41], QRS duration [HR 1.08 per 10 ms increase (95% CI 0.98–1.19), P = 0.13] and QTc-time [HR 0.95 per 10 ms increase (95% CI 0.88–1.03), P = 0.19]. The PR-interval was, however, significantly associated with LTVA [HR 1.06 per 10 ms increase (95% CI 1.00–1.13), P = 0.04]. The results of this model are depicted in Supplementary material online, Table S1.

Prediction of LTVA with FactorECG

The VAE compressed the ECG data into 21 different ECG factors and their factor traversals are available in Supplementary material online, Figure S1. In Cox regression, F8 [HR 1.60; 95% CI (1.29–1.99), P < 0.005], F32 [HR 0.77; 95% CI (0.62–0.95), P = 0.02], F27 [HR 0.71; 95% CI (0.57–0.88), P < 0.005], and F32 [HR 1.26, 95% CI (1.03–1.55), P = 0.03] were significantly associated with the outcome after correcting for guideline indication (NYHA II/III and LVEF < 35%, P = 0.84). C-statistic for the model was 0.67 (95% CI 0.62–0.72). A reconstruction of the significant generative factors (F8, F15, F25, F27, and F32) has been illustrated in Figure 2. F8 encodes for PR-interval and P-wave morphology, where high values increase PR-interval and broaden the P-wave. F15 encodes for P-wave height and P/T-overlap, where low values are correlated with atrial fibrillation and third-degree AV-block. F25 encodes for conduction delays in the right bundle (right bundle branch block), where low values increase the block. F27 encodes for P- and R-axis deviation, where low values flatten out the P-wave. F32 encodes for QRS-T amplitudes, with low values reconstruct QRS-T microvoltages. Results of the Cox regression model and the descriptions of the generative factors are present in Table 2 and Supplementary material online, Table S2. The partial effects on outcome per significant factor have been plotted in Supplementary material online, Figure S2. As an example, the ECGs and their corresponding values of the generative factors of two patients were plotted in Figure 3. A summary figure of this study was depicted in Figure 4. To address the possible effect of cardiac memory after pacing, a subgroup analysis was run excluding patients with a pacemaker (n = 32) which showed similar factors to be important (Supplementary material online, Table S3).

LA dimensions

To investigate the possibility that the identified factors were an effect of anatomical substrates of P-wave abnormalities, such as atrial remodelling, first and last LAVI and LA dimensions (by outcome) of complete UMCU cases (n = 219) were plotted (Supplementary material online, Table S4).
LA’s were significantly larger in the last echocardiography, compared with the first ($P = 0.02$, Supplementary material online, Figure S6). Next, the relationship of LA dimensions with the significant factors was plotted (Supplementary material online, Figure S8) which showed no association between $F_8$, $F_{15}$, $F_{25}$, $F_{27}$, and $F_{32}$ and LA dimensions.

**Figure 2** Factor traversals for the ECG factors that were associated with LTVA in the DCM cohort. We start with a mean FactorECG for this population (i.e. the mean value of the 21 ECG factors) and reconstruct an ECG using the decoder (white). Subsequently, for each individual ECG factor, values between $-4$ (blue) and 4 (red) are added and ECGs are reconstructed for every value. Meanwhile, values for the other factors are kept constant. This way we are able to visualize the effect of a single ECG factor on the median beat ECG morphology in this cohort. For factors 8 and 32, high values of the factors were associated with a higher risk of LTVA (left). For factors 15, 25, and 27, conversely, low values of the factors were associated with a higher risk of LTVA (right). The FactorECG decoder reconstructs the full 12-lead median beat ECG, a selection of leads is shown in this figure. DCM, dilated cardiomyopathy; LTVA, life-threatening ventricular arrhythmia.
Table 2 Cox proportional hazards model of generative factors in both cohorts

| Factors | Factor descriptions | Hazard ratio | 95% CI      | P-value |
|---------|---------------------|--------------|-------------|---------|
| F1      | Inferolateral ST deviation | 0.91 | 0.72–1.14 | 0.39 |
| F5      | Inferolateral T-wave height and orientation | 1.17 | 0.92–1.48 | 0.19 |
| F6      | P-wave height and/or shape | 1.14 | 0.90–1.44 | 0.27 |
| F8⁻     | PR-interval (high values associated with first degree AV-block and reduced LVEF) | 1.61 | 1.29–1.99 | <0.005 |
| F9      | T-wave height and orientation | 1.12 | 0.89–1.39 | 0.34 |
| F10     | Ventricular rate | 0.93 | 0.76–1.13 | 0.46 |
| F11     | Subtle P- and T-wave changes | 1.00 | 0.83–1.21 | 0.97 |
| F12     | Onset of depolarization | 1.08 | 0.86–1.36 | 0.50 |
| F13     | Anterior ST deviation | 0.85 | 0.68–1.06 | 0.14 |
| F15⁻    | P-wave height and P/T-overlap (low values associated with third-degree AV-block and junctional tachycardia) | 0.81 | 0.66–0.99 | 0.04 |
| F16     | T-wave morphology | 1.14 | 0.94–1.40 | 0.19 |
| F17     | Lateral ST deviation | 1.08 | 0.85–1.38 | 0.51 |
| F19     | Precordial R-wave progression and combined P-QRS-T-amplitude | 1.07 | 0.87–1.33 | 0.51 |
| F22     | Subtle T-wave changes | 1.02 | 0.83–1.25 | 0.85 |
| F23     | P-wave height and/or shape | 1.13 | 0.93–1.37 | 0.21 |
| F26⁻    | Right bundle branch delay (low values associated with ventricular tachycardia, RBBB, and reduced LVEF) | 0.77 | 0.62–0.95 | 0.02 |
| F26     | Left bundle branch delay | 1.02 | 0.81–1.29 | 0.85 |
| F27⁻    | P- and R-axis deviation (low values associated with AF, junctional bradycardia, ventricular tachycardia, and left axis deviation) | 0.71 | 0.57–0.88 | <0.005 |
| F30     | QR interval | 0.92 | 0.74–1.16 | 0.48 |
| F31     | QRS-T amplitudes | 0.86 | 0.71–1.05 | 0.15 |
| F32⁻    | QRS-T amplitudes (high values associated with microvoltages) | 1.26 | 1.02–1.55 | 0.03 |

Results of Cox regression and explanation of (significant) factors including their association with known electrocardiographic and echocardiographic pathologies as described in Van de Leur and Bos et al.⁸

*Significant.

Discussion

This is the first study to use an explainable DNNs trained with (baseline) ECGs for LTVA prediction in DCM patients on a multicentre dataset. By using an inherently explainable DNN architecture, we were able to distinguish patients at risk for LTVA whilst allowing interpretation and visualisation of pivotal ECG features.⁷ The model was able to identify patients at the highest risk with a predominant network focus on P-wave abnormalities. Furthermore, these identified P-wave abnormalities did not correlate to their anatomical analogues (LA dimension/LAVI), suggesting an electrophysiological substrate.

FactorECG findings in relation to prior studies

The FactorECG encompasses the median beat ECG, including most of its features, into 21 generative factors of variation (https://dcm.ecgx.ai). This novel strategy allows to simultaneously evaluate most characteristics that make up an ECG automatically in much smaller datasets, rather than using selected and human-derived ECG features. Overall, the factors that were most predictive for LTVA primarily encoded for several P-wave characteristics, such as PR-duration, P-wave morphology, and P-wave axis (Figure 2). The combination of reconstructed ECGs together with the hazard ratios allows for a novel in-depth interpretation of a DNN’s features. A high value in F₂ for instance, leads to PR-prolongation with a broadened P-wave, whereas a low value in F₂₇ leads to removal of the P-wave, which is associated with atrial fibrillation, a known clinical risk factor for LTVA in DCM.³ Because the baseline model using established ECG variables performed poorly, this indicated that the VAE generative factors are more complex than solely the standard ECG intervals. The combination of the 21 generative factors as well as their interpretation allows for LTVA prediction and feature detection (Figure 3).

The fact that atrial (i.e. P-wave) abnormalities predict ventricular events (i.e. LTVA) may be considered remarkable. However, this association has been described before, and has been thought to be due to shared mechanistic pathologies between atria and ventricles, such as ion-channel abnormalities, or atrioventricular fibrosis due to atrial remodelling.⁵,⁶,¹³ In a recently published population study of 13 580 participants, abnormal P-wave indices were independently associated with LTVA, after adjustment for age, sex, race, and study centre.¹⁴ As it is likely that these P-wave indices are caused by atrial remodelling, we investigated the association of anatomical LA characteristics and our identified ECG factors. As expected, LA
Figure 3  Kaplan–Meier curve and examples for the predictive value of factor 8. A Kaplan–Meier (A) for factor 8 and (B) two ECGs of patients with a low and high predicted 5-year LTVA risk are depicted. The values for each factor are depicted below the ECG, along with the outcomes of the patient. The ECG on the left had a low value for factor 8, corresponding to a short PR and P-wave duration: this patient had a low predicted risk of LTVA and did not reach the endpoint. The ECG on the right had a high value for factor 8, corresponding to a broad P-wave with a long PR-interval: this patient had a high predicted risk of LTVA and reached the outcome.

Predicted 5-year LTVA risk: 9.7%
True time-to-LTVA: never (5.3 years FU)

Predicted 5-year LTVA risk: 83%
True time-to-LTVA: 0.8 years
Study Population

Dilated Cardiomyopathy

**12-lead baseline ECG:**
- Adult patients with non-ischemic non-valvular dilated cardiomyopathy (<45%)
- Follow-up available
- ECG before LVAD and HTx
- ECG not paced
- Excluding CRT implantation

**Composite outcome:**
- LTVA defined as: Sustained VT (>100 bpm, >30 seconds or haemodynamic compromise), VF, SCD or appropriate ICD therapy
- LTVA prior to HTx

Methods

**DCM ECGs**
(n = 317, 90 with outcome (28%))

**DCM ECGs**
(n = 378, 25 with outcome (6%))

**Pretraining phase**
VAE training with 1,114,332 12-lead 10 second ECGs of 251,473 unique patients (UMCU)
Compression of ECG signal into 21 generative factors

**Training phase**
Cox-regression

**Results**

| Factor 8 | Factor 15 | Factor 25 | Factor 27 | Factor 32 |
|----------|-----------|-----------|-----------|-----------|
| HR 1.60 [1.29-1.99] | HR 0.81 [0.66-0.99] | HR 0.77 [0.62-0.95] | HR 0.71 [0.57-0.88] | HR 1.26 [1.03-1.55] |
| p = 0.005 | p = 0.04 | p = 0.02 | p < 0.005 | p = 0.03 |

**Not associated with LTVA**
Ventricular rate (p = 0.61)
QRS-duration (p = 0.10)
QTc-time (p = 0.24)
ICD guideline indication (p = 0.84)

Figure 4: Study summary figure, including the methods and results. The study population were patients with dilated cardiomyopathy, in which an explainable pre-trained deep neural network (FactorECG) was trained for the outcome of life-threatening ventricular arrhythmias. This network encoded the median beat ECG into 21 factors to generate an ECG using only these factors, allowing to evaluate most characteristics that make up an ECG automatically, in a relatively small dataset. LVAD, left ventricular assist device. HTx, heart transplantation; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; VT, ventricular tachycardia; VF, ventricular fibrillation; SCD, sudden cardiac death; ICD, implantable cardioverter-defibrillator; HR, hazard ratio; UMCU, University Medical Centre Utrecht; MUMC+ = Maastricht University Medical Centre.
dimensions increased significantly over time, indicating disease progression. However, we did not find any association to the significant ECG factors, suggesting an exclusive electrophysiological substrate. This is in line with other reports, in which individual ECG P-wave changes were not reliable predictors of anatomic atrial enlargement.15,16

Myocardial fibrosis is often seen in patients with DCM and may cause zones of slow conduction in the myocardium, resulting in zigzag pathways that are prone to causing ventricular tachycardias.17 These cellular mechanisms may be visible on the ECG as increased QRS duration and bundle branch block or low voltages. In this study, F25 reflected increased QRS duration in case of right bundle branch blocks and was associated with LTVA as well. Left bundle branch block (F26), however, was not associated with LTVA. As these patients generally are CRT recipients which were excluded from our analyses, this may have caused an underestimation of the effect of left bundle branch blocks in our model. Lower voltages seem to be reflected in the FactorECG in F32, which is also associated with LTVA. More complex electrocardiographic markers, such as QRS fractionation, T-wave alternans, and QRS-T angle, have also been proposed.1 QRS fractionation and T-wave abnormalities, however, did not appear as an explanatory ECG variable in our model. T-wave alternans (defined as changing T-wave morphology, occurring in each alternant beat) has been repeatedly associated with LTVA in DCM, but cannot be measured in the single ECG median beat that is used in the current research. All these ECG markers are limited by standardization difficulties, which may be decreased by (automatic) interpretation using DNNs.1,4,18,19 As these networks are generally ‘black-box’ algorithms that need very large datasets for training, a strategy of reducing the ECG into its generative factors was used. These interpretable factors were then used in a common statistical model (Cox regression), that allowed for pivotal ECG features to be visualized.

Future studies are warranted to prospectively validate the identified ECG abnormalities and their electrophysiological substrate for LTVA prediction in DCM, including a comparison with accepted risk factors for LTVA. Since longer PR-interval and wide QRS duration were associated with LTVA, assessment of the value of hemi-blocks may also be considered. Importantly, the addition of prolonged measurements (such as exercise tests or Holter for T-wave alternans) in DNNs remains to be investigated.

Genotype–phenotype associations

DCM has a genetic basis in 30–50% of cases and specific genotype–phenotype associations are known to lead to arrhythmogenic phenotypes. One study analysed over 75,000 ECGs from the UK Biobank and established several genetic ECG signatures. A polygenic effect on PR-interval for instance, was identified, as well as genetic variants related to the Q-wave in DCM. The strongest Q-wave locus was discovered in BAG3: a gene in which pathogenic variants have been described for DCM with high penetrance and a high risk of progressive heart failure.20 As our VAE model assessed the entire ECG, an interesting significant factor included QRS-T voltages (F32), with high voltages in this factor associated with microvoltages. These microvoltages are an established ECG characteristic for phospholamban cardiomyopathy, which can lead to both a highly arrhythmogenic DCM phenotype and arrhythmogenic cardiomyopathy.2 Integrating

Limitations

This study has several limitations to address. Given the nature of retrospective cohorts, data may contain missingness not at random and bias may be present requiring prospective evaluation of the findings. As the UMCU is a heart transplantation centre, this may have caused a selection bias. To account for this, an external cohort was added from the MUMC+ (non-heart transplantation centre) of which the patients logically presented with less severe phenotypes (Table 1). Unfortunately, the characteristics of the implanted ICDs in this population were not available, which may have biased our findings. More importantly, since ICD shocks are not a true surrogate for sudden cardiac death in patients with DCM, the results need confirmation in a study population with fewer ICD carriers or considering only fast events (i.e. >250/min).23 Because DCM is relatively rare, the results may be due to sample size and require confirmation in larger (prospective) studies.

Conclusion

To the best of our knowledge, this study is the first to use interpretable DNNs trained with ECGs for LTVA prediction in DCM patients. We observed that the VAE network combined with an interpretable Cox regression can distinguish patients at risk of LTVA. The use of this inherently explainable DNN pipeline allowed interpretation and visualisation of pivotal ECG features.7 While the VAE network encompasses the complete ECG, predictions were mainly driven by P-wave abnormalities that did not correlate with LA dimensions, suggesting an electrophysiological substrate. Future studies are warranted to validate these findings and elucidate their electrophysiological substrate for LTVA prediction in DCM.

Supplementary material

Supplementary material is available at Europace online.

Funding

This study was financed by The Netherlands Organisation for Health Research and Development (ZonMW) with grant number 104021004 and the Dutch Heart Foundation with grant number 2019B011. A.S. is supported by the Alexandre Suerman Stipendium. F.W.A. is supported by UCL Hospitals NIHR Biomedical Research Centre and CVON-AI: 2018B017. P.A.D. is supported by the Fondation Leducq CURE-PLaN. A.S., M. t.R. is supported by the Netherlands Heart Foundation (2015T058), the UMC Utrecht Fellowship Clinical Research Talent, and CVON eDETECT. This work is further supported by the Netherlands Cardiovascular Research Initiative, with the support of the Dutch Heart Foundation (CVON 2015-12 eDETECT) and by the focus area of Applied Data Science at Utrecht University, The Netherlands.

Conflicts of interest: None declared.
Data availability
The dataset is not available due to patient privacy restrictions.

References
1. Sammani A, Kayvanpour E, Bosman LP, Sedaghat-Hamedani F, Proctor T, Gi W, et al. Predicting sustained ventricular arrhythmias in dilated cardiomyopathy: a meta-analysis and systematic review. ESC Heart Fail 2020; 7:1430–1441.
2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021; 42:ehab368.
3. Kayvanpour E, Sammani A, Sedaghat-Hamedani F, Lehmann DH, Broezel A, Koelmemenolu J, et al. A novel risk model for predicting potentially life-threatening arrhythmias in non-ischemic dilated cardiomyopathy (DCM-SVA risk). Int J Cardiol 2021; 339:75–82.
4. van de Leur RR, Boonstra MJ, Bagheri A, Roudijk RW, Sammani A, Taha K, et al. Big data and artificial intelligence: opportunities and threats in electrophysiology. Arrhythmia Electrophysiol Rev 2020; 9:146–154.
5. Ko W-Y, Siantis KC, Atza ZI, Carter RE, Kapa S, Ommen SR, et al. Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram. J Am Coll Cardiol 2020; 75:722–733.
6. van de Leur RR, Blom LJ, Gaves E, Hof IE, van der Heijden JF, Clappers NC, et al. Automatic triage of 12-lead ECGs using deep convolutional neural networks. J Am Heart Assoc 2020; 9:e015138.
7. Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell 2019; 1:206–215.
8. van de Leur RR, Bos MN, Taha K, Sammani A, van Duijvenboden S, Lambaie PD, et al. Inherently explainable deep neural network-based interpretation of electrocardiograms using variational auto-encoders. medRxiv 2022.
9. van de Leur R, Taha K, Bos MN, van der Heijden JF, Gupta D, Cranmer MJ, et al. Discovering and visualizing disease-specific electrocardiogram features using deep learning: proof-of-concept in phospholamban gene mutation carriers. Circ Arrhythm Electrophysiol 2021; 14:e009056.
10. Sapp JL, Parkash R, Wells GA, Yetisir E, Gardner MJ, Healey JS, et al. Cardiac resynchronization therapy reduces ventricular arrhythmias in primary but not secondary prophylactic implantable cardioverter defibrillator patients: insight from the resynchronization in ambulatory heart failure trial. Circ Arrhythm Electrophysiol 2017; 10:e004875.
11. Sammani A, Jansen M, Linschoten M, Bagheri A, de Jonge N, Kerkels H, et al. UNRAVEL: big data analytics research data platform to improve care of patients with cardiomyopathies using routine electronic health records and standardised bio-banking. Neth Heart J 2019; 27:426–434.
12. Higgins I, Matthey L, Pal A, Burgess C, Giorot X, Botvinick M, et al. Beta-VAE: learning basic visual concepts with a constrained variational framework. Conference Track Proceedings 5th International Conference on Learning Representations; 2018.
13. Spezzacatene A, Sinagra G, Merlo M, Barbati G, Graw SL, Brun F, et al. Arrhythmogenic phenotype in dilated cardiomyopathy: natural history and predictors of life-threatening arrhythmias. J Am Heart Assoc 2015; 4:e002149.
14. Maheshwari A, Norby FL, Soliman EZ, Alonso A, Sotoodehnia N, Chen LY. Association of P-wave abnormalities with sudden cardiac and cardiovascular death: the ARIC study. Circ Arrhythm Electrophysiol 2021; 14:e009314.
15. Tsao CW, Josephson ME, Hauser TH, O’Halloran TD, Agarwal A, Manning WJ, et al. Accuracy of electrocardiographic criteria for atrial enlargement: validation with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10:1–7.
16. Truong QA, Charipar EM, Piazzek LM, Taylor C, Fontes JD, Kriegel M, et al. Usefulness of electrocardiographic parameters as compared with computed tomography measures of left atrial volume enlargement: from the ROMICAT trial. J Electrocardiol 2011; 44:257–264.
17. de Bakker JM, van Capelle FJ, Janse MJ, Tasseron S, Vermeulen JT, de Jonge N, et al. Slow conduction in the infarcted human heart. “Zigzag” course of activation. Circulation 2018; 188:915–926.
18. Pei J, Li N, Gao Y, Wang Z, Li X, Zhang Y, et al. The J wave and fragmented QRS complexes in inferior leads associated with sudden cardiac death in patients with chronic heart failure. European 2012; 14:1180–1187.
19. Vandenberk B, Robyns T, Goovaerts G, Claeyts M, Helsen F, Soest SV, et al. Inter- and intra-observer variability of visual fragmented QRS scoring in ischemic and non-ischemic cardiomyopathy. J Electrocardiol 2018; 51:549–554.
20. Verweij N, Benjamini J-Y, Morley MP, van de Vege YJ, Teumer A, Trenkwalder T, et al. The genetic makeup of the electrocardiograph. Cell Syst 2020; 11:229–238.e5.
21. Meder B, Rühl F, Weis T, Homuth G, Keller A, Franke J, et al. A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. Eur Heart J 2014; 35:1069–1077.
22. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med 2020; 12:44.
23. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006; 113:776–782.